US equities |
NVDA $233.95 ▲+1.34% MU $1,074.89 ▼-2.05% TSLA $370.59 ▲+4.65% SPCX $158.96 ▲+7.35% SNDK $1,719.99 ▼-3.79% AMD $633.91 ▲+2.95% STX $848.99 ▼-10.21% INTC $119.33 ▼-0.56%
FinancialContent

Verona Pharma plc - American Depositary Shares (NQ:VRNA)

106.91 UNCHANGED
Last Price Updated: 4:00 PM EDT, Oct 6, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Verona Pharma plc - American Depositary Shares

News headline image
Merck Completes Acquisition of Verona Pharma
From Merck & Co., Inc.
Via Business Wire
News headline image
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates VRNA, DALN, RGLD on Behalf of Shareholders
From Halper Sadeh LLC
Via GlobeNewswire
News headline image
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates VRNA, KLG, MRGM, SONN on Behalf of Shareholders
From Halper Sadeh LLC
Via GlobeNewswire
News headline image
VERONA PHARMA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Verona Pharma plc - VRNA
From Kahn Swick & Foti, LLC
Via Business Wire
News headline image
VRNA Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Verona Pharma plc Is Fair to Shareholders
From Halper Sadeh LLC
Via Business Wire
News headline image
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Verona Pharma plc (Nasdaq - VRNA), Olo Inc. (NYSE - OLO), Guaranty Bancshares, Inc. (NYSE - GNTY), MRC Global Inc. (NYSE - MRC)
From Brodsky & Smith LLC
Via GlobeNewswire
News headline image
Merck to Acquire Verona Pharma, Expanding its Portfolio to Include Ohtuvayre® (ensifentrine), a First-In-Class COPD Maintenance Treatment for Adults and Expected to Drive Growth into the Next Decade
From Merck & Co., Inc.
Via Business Wire
News headline image
Small-Cap Catalyst Pharma Is Among Market's Best Price Performers
Small-cap biotech Catalyst Pharmaceuticals has been outperforming the broader market amid earnings and revenue acceleration. It joined the S&P 600 last month. 
Via MarketBeat
Topics Stocks
News headline image
Verona Pharma (NASDAQ: VRNA) Reports its Phase 3 ENHANCE-2 Trial of Ensifentrine Met Primary Endpoint in Treating COPD
Verona Pharma plc (NASDAQ: VRNA) is engaged as a clinical-stage biopharmaceutical company, which is focused on the research, development and 
Via Spotlight Growth
The Healthcare Companies Fighting the World’s Biggest Killers
Palm Beach, FL – July 13, 2022 – FinancialNewsMedia.com News Commentary – Some of the most prevalent health conditions on the planet claim millions of lives every year. Companies from across the... 
Via FinancialNewsMedia